bioAffinity Technologies' (NASDAQ:BIAF – Get Rating) lock-up period will end on Tuesday, February 28th. bioAffinity Technologies had issued 1,282,600 shares in its IPO on September 1st. The total size of the offering was $7,862,338 based on an initial share price of $6.13. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the end of the lock-up period.
bioAffinity Technologies Stock Down 7.2 %
Shares of BIAF opened at $2.06 on Tuesday. The company's fifty day moving average is $2.00. bioAffinity Technologies has a 1-year low of $1.31 and a 1-year high of $15.55.
Get bioAffinity Technologies alerts:Institutional Trading of bioAffinity Technologies
An institutional investor recently bought a new position in bioAffinity Technologies stock. Jane Street Group LLC bought a new position in bioAffinity Technologies, Inc. (NASDAQ:BIAF – Get Rating) during the third quarter, according to its most recent disclosure with the SEC. The firm bought 11,004 shares of the company's stock, valued at approximately $32,000. Jane Street Group LLC owned 0.40% of bioAffinity Technologies as of its most recent filing with the SEC. 2.43% of the stock is owned by hedge funds and other institutional investors.
bioAffinity Technologies Company Profile
(Get Rating)
bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level.
Featured Stories
- Get a free copy of the StockNews.com research report on bioAffinity Technologies (BIAF)
- Is Alibaba the Jet fuel Launching China into New Frontiers?
- Applied Materials Is In The Semiconductor Sweet Spot
- Can Coinbase Shake Off Regulatory Risk After Kraken's Shakedown?
- Tripadvisor Stock Gap and Crap. Here's Why.
- Could Copper be the Shiny Object That Lifts Barrick Gold?
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.